Canada Research Roundup: Cronos Group, Prometic Life Sciences, Vivo Cannabis

Roots

05/06/2019 13:07

June 5 (Reuters) - Securities analysts revised their ratings and price targets on several Canadian
companies, including Cronos Group, Prometic Life Sciences and Vivo Cannabis, on Wednesday. 
    
    
  HIGHLIGHTS
     * Cronos Group Inc  CRON.TO : BofA Merrill Lynch raises to buy from underperform
     * Prometic Life Sciences Inc  PLI.TO : RBC cuts to sector perform from outperform
     * Vivo Cannabis Inc  VIVO.V : Canaccord Genuity cuts target price to C$1.80 from C$2
 Following is a summary of research actions on Canadian companies reported by Reuters on Wednesday. Stock
entries are in alphabetical order. 
            
     * Brp Inc  DOO.TO : Citigroup raises target price to C$49 from C$45
     * Canadian National Railway Co  CNR.TO : RBC cuts target price to C$127 from C$128
     * Cronos Group Inc  CRON.TO : BofA Merrill Lynch raises to buy from underperform
     * Cronos Group Inc  CRON.TO : BofA Merrill Lynch raises target price to C$27 from C$17
     * Dollarama Inc  DOL.TO : BMO raises target price to C$45 from C$35
     * Prometic Life Sciences Inc  PLI.TO : RBC cuts to sector perform from outperform
     * Prometic Life Sciences Inc  PLI.TO : RBC cuts price target to C$0.03 from C$0.70
     * Roots Corp  ROOT.TO : National Bank of Canada cuts target price to C$5.50 from C$6.50
     * Vivo Cannabis Inc  VIVO.V : Canaccord Genuity cuts target price to C$1.80 from C$2
 

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))